Functional Consequences of Complementarity-determining Region Deactivation in a Multifunctional Anti-nucleic Acid Antibody*

Received for publication, August 6, 2013, and in revised form, October 2, 2013. Published, JBC Papers in Press, October 23, 2013, DOI 10.1074/jbc.M113.508499

Jiyeon Lee‡, Hye-Jin Kim§, Jooho Roh‡, Youngsil Seo‡, Minjae Kim‡, Hye-Ryeong Jun§, Chuong D. Pham§, and Myung-Hee Kwon‡§†

From the ‡Department of Biomedical Sciences, Graduate School, Ajou University, San 5, Woncheon-dong, Yeongtong-gu, Suwon 443-749, South Korea and §Department of Microbiology, Ajou University School of Medicine, San 5, Woncheon-dong, Yeongtong-gu, Suwon 443-749, South Korea

**Author’s Choice—Final version full access.

Many murine monoclonal anti-DNA antibodies (Abs) derived from mice models for systemic lupus erythematosus have additional cell-penetration and/or nucleic acid-hydrolysis properties. Here, we examined the influence of deactivating each complementarity-determining region (CDR) within a multifunctional anti-nucleic acid antibody (Ab) that possesses these activities, the catalytic 3D8 single chain variable fragment (scFv). CDR-deactivated 3D8 scFv variants were generated by replacing all of the amino acids within each CDR with Gly/Ser residues. The structure of 3D8 scFv accommodated single complete CDR deactivations. Different functional activities of 3D8 scFv were affected differently depending on which CDR was deactivated. The only exception was CDR1, located within the light chain (LCDR1); deactivation of LCDR1 abolished all of the functional activities of 3D8 scFv. A hybrid Ab, HW6/3D8L1, in which the LCDR1 from an unrelated Ab (HW6) was replaced with the LCDR1 from 3D8, acquired all activities associated with the 3D8 scFv. These results suggest that the activity of a multifunctional 3D8 scFv Ab can be modulated by single complete CDR deactivation and that the LCDR1 plays a crucial role in maintaining Ab properties. This study presents a new approach for determining the role of individual CDRs in multifunctional Abs with important implications for the future of Ab engineering.

Autoantibodies against DNA play a major role in the pathogenesis of the autoimmune disease systemic lupus erythematosus (1, 2). Monoclonal antibodies (mAb) against DNA isolated from murine lupus models, such as MRL-lpr/lpr mice and (NZB/NZW)F1 mice, and from systemic lupus erythematosus patients have a high frequency of positively charged residues in their complementarity-determining regions (CDRs).2 These basic residues contribute to high affinity DNA binding (3–5). Apart from their DNA binding properties, many anti-DNA mAbs derived from mice and humans have additional activities, such as cell-penetration (6–11), DNA hydrolysis and/or RNA-hydrolysis (12), or both (13, 14). However, despite accumulating evidence for the multifunctional properties of anti-DNA mAbs, few studies have addressed their structural and functional features with respect to cell-penetration (7) or DNA hydrolysis (15).

3D8 single chain variable fragment (scFv) is a murine catalytic anti-nucleic acid Ab that has nucleic acid (dsDNA, ssDNA, and RNA) binding and hydrolysis properties and cell-penetrating activity (14, 15). We reported previously the results of a mutational analysis based on the x-ray crystallographic structure of 3D8 scFv, which showed that the His residues in CDR1 of the heavy chain (HCDR1) and CDR3 of the light chain (LCDR3) are critical for DNA hydrolysis (15). 3D8 scFv is endocytosed via the caveolae-mediated pathway and localizes to the cytosol without translocating to the nucleus (14, 16). Moreover, we found that the activities of 3D8 scFv are relatively tolerant of alteration of the CDR. That is, replacing the entire HCDR3 sequence with a Tat48–60 peptide sequence did not impair the DNA binding, DNA-hydrolyzing, or cell-penetrating activities of 3D8 scFv (17). This indication that the CDRs of 3D8 scFv are capable of accommodating multiple sequence changes together with reports that peptides derived from the CDRs of other Abs maintain functions similar to the original Ab (10, 18–20) prompted us to study the role of each CDR in the DNA binding.

* This work was supported by the Science Research Center Program (2011-0030043) and the Basic Science Research Program (2011-0007358) of the National Research Foundation of Korea and a grant (2011) from the Department of Medical Sciences, the Graduate School, Ajou University.

† To whom correspondence should be addressed: Dept. of Microbiology, Ajou University School of Medicine, Medicine, Woncheon-dong 5, Suwon 443-749, Korea. Tel.: 82-31-219-5074; Fax: 82-31-219-5079; E-mail: kwonmh@ajou.ac.kr.

‡ The abbreviations used are: CDR, complementarity-determining region; scFv, single chain variable fragment; FR, framework region; SPR, surface plasmon resonance; HCDR, heavy chain; LCDR, light chain; Ab, antibody.

1 To whom correspondence should be addressed: Dept. of Microbiology, Ajou University School of Medicine, Medicine, Woncheon-dong 5, Suwon 443-749, Korea. Tel.: 82-31-219-5074; Fax: 82-31-219-5079; E-mail: kwonmh@ajou.ac.kr.

2 The abbreviations used are: CDR, complementarity-determining region; scFv, single chain variable fragment; FR, framework region; SPR, surface plasmon resonance; HCDR, heavy chain; LCDR, light chain; Ab, antibody.
CDR deactivation in a Multifunctional Anti-nucleic Acid Antibody

DNA-hydrolyzing, and cell-penetrating properties of 3D8 scFv through a complete CDR-scaled change (single complete CDR-deactivation) rather than the more commonly employed point mutation analysis of individual CDR residues.

The purpose of this study was to investigate the role of each CDR in the activities of 3D8 scFv by analyzing the effect of single complete CDR deactivations. To do this we generated six CDR-deactivated 3D8 scFv variants, each of which contained one CDR in which all the amino acid residues were replaced with a non-charged flexible sequence of repeated Gly/Ser residues, and examined both their secondary structures and their DNA binding, DNA-hydrolysis, and cell-penetration activities. Moreover, to clarify the role of LCDR1 in 3D8 activities, we performed biochemical examination of the peptides corresponding to the 3D8 CDRs as well as a hybrid Ab, HW6/3D8L1, in which the LCDR1 of human HW6 (an anti-death receptor 5 (DR5) Ab) was replaced with the LCDR1 from 3D8.

EXPERIMENTAL PROCEDURES

ScFv Proteins and Peptides—CDR-replaced VH (variable domain of heavy chain) and VL (variable domain of light chain) genes were synthesized by GenScript Inc. The genes were sub-cloned into the plg20 vector, which contains a Protein A tag (7 kDa), using XmaI and NcoI restriction sites. This resulted in the plg20-scFv expression vector in which VH and VL are connected by a (Gly-4/Ser-1)3 linker. ScFv proteins were expressed in bacteria and purified from bacterial culture supernatants in a soluble form by IgG-Sepharose chromatography (15). The concentrations of scFv proteins (mg ml \(^{-1}\)) were determined using extinction coefficients at 280 nm, which were calculated from the respective amino acid sequences. Peptides N-terminally labeled with either FITC or biotin were synthesized by Peptron Inc. (Korea).

Circular Dichroism (CD) Spectroscopy—The far-UV CD spectra of scFv proteins were recorded on a J-20 spectropolarimeter (Jasco Inc., Japan) at a concentration of 0.5–1.0 mg/ml in Tris buffer (10 mM Tris-HCl, 10 mM NaCl, pH 7.4) at 25 °C. scFvs were diluted in HBS-EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA) containing 0.005% surfactant P-20. The same buffer was used as the running buffer. The substrate, ss-(dN)40 DNA labeled with biotin at the 5’ terminus (bio-ss-(dN)40, 5’-CCATGAGTGATAACACTGCGGCCAACTTACTTCTG- ACAAC-3’), was generated by Integrated DNA Technologies Inc. Brieﬂy, ss-(dN)40 DNA (1 \(\mu\)M) was immobilized on a streptavidin-coated sensor chip SA (Amersham Biosciences) at a level of 200–800 response units. 3D8-Hi proteins (serially diluted from 250 to 0.8 nm) and 3D8-Li proteins (serially diluted from 200 to 0.4 nm) were injected into the flow cell for 3 min at a flow rate of 30 \(\mu\)l/min. All kinetic parameters were calculated by nonlinear regression analysis according to a 1:1 binding model using BIA evaluation software (Version 3.2). The dissociation constant, \(K_{D}\), was calculated using the formula \(K_{D} = k_{off}/k_{on}\), where \(k_{off}\) and \(k_{on}\) are the dissociation and association rate constants, respectively.

Flow Cytometry—To detect internalized scFvs, HeLa cells were seeded in 6-well plates at a density of 5 \(\times\) 10\(^4\) cells/well and incubated with 5 \(\mu\)M scFvs in serum-free medium for 6 h at 37 °C. The cells were washed 3 times with ice-cold PBS and fixed with 4% paraformaldehyde-PBS for 10 min at 4 °C. After washing with PBS, cell membranes were permeabilized with “P” buffer (1% BSA, 0.1% saponin, and 0.1% sodium azide in PBS) and incubated with rabbit IgG (2 \(\mu\)g/ml) followed by FITC-anti-rabbit IgG. Each incubation step was performed for 1 h at 4 °C followed by washing with ice-cold PBS. Finally, the cells were suspended in 4% paraformaldehyde-PBS and analyzed using a FACSCan II flow cytometer (BD Biosciences). In some cases the permeabilization step was omitted. To detect internalized peptides, HeLa cells were incubated with 10 \(\mu\)M FITC-labeled peptides in serum-free TOM™ medium for 2 h at 37 °C. The cells were then fixed and analyzed by flow cytometry.

Confocal Microscopy—To detect scFvs, HeLa cells were seeded on glass coverslips in 24-well plates at a density of 4 \(\times\) 10\(^4\) cells/well and incubated with 5 \(\mu\)M scFvs in serum-free medium for 6 h at 37 °C. Cells were washed, fixed, and permeabilized as described for flow cytometry experiments. To detect peptides, HeLa cells were incubated with 10 \(\mu\)M FITC-labeled peptides in serum-free medium for 2 h at 37 °C and then fixed. The cell nuclei were stained with Hoechst 33342 (Vector Laboratories) for 30 min at room temperature. Images were obtained using a laser scanning confocal fluorescence microscope (model LSM710, Carl Zeiss).

Enzyme-linked Immunosorbent Assay (ELISA)—To assay the heparin binding activity of scFvs, various concentrations (1.3–10 \(\mu\)g/ml) of scFvs were incubated in 96-well polystyrene plates coated with heparin (10 \(\mu\)g/ml; Sigma). To assay DNA binding activity, scFvs were incubated in wells coated with bio-ss-(dn)40 DNA (1 \(\mu\)M). Bound proteins were detected using rabbit IgG (Sigma) followed by alkaline phosphatase-conjugated anti-rabbit IgG (Pierce) as described previously (15). To assay the binding of peptides to heparin or DNA, biotin-labeled peptides were incubated in wells coated with pUC57 plasmid DNA (2 \(\mu\)g/ml) or heparin (10 \(\mu\)g/ml). Bound peptides were detected using alkaline phosphatase-conjugated streptavidin (Invitrogen) and p-nitrophenyl phosphate substrate (Sigma). To assay the human DR5 binding activity of scFvs, wells were coated with DR5 protein (2 \(\mu\)g/ml) obtained from PeproTech.

Fluorescence Resonance Energy Transfer (FRET)-based DNA Cleavage Assay—A DNA substrate composed of 21 nucleotides labeled with 6-carboxylfluorescein (FAM) at the 5’ terminus and a black hole quencher (BHQ) at the 3’ terminus (5’-FAM-CGATGAGTGCCATGGATATAC-BHQ3’) was generated by M-Biotech. scFvs (1 \(\mu\)M), peptide (1 \(\mu\)M), or DNase I (1 unit) was either preincubated or not with heparin (a competitor molecule; 10 \(\mu\)g/ml) for 10 min at room temperature before being loaded into the wells of a 96-black-well plate containing DNA substrate (250 nm). Immediately after addition to the DNA substrate, the fluorescence intensity was read in real time over a period of 6 h at 37 °C in a fluorescence detector (Molecular Devices). Each reaction was brought to a final volume of 100 \(\mu\)l.
with TBSM buffer (100 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM MgCl₂).

RESULTS

Production of scFv Variants—ScFv proteins were purified to homogeneity as soluble proteins with molecular masses of ~34 kDa (Fig. 1). Approximately 1–5 mg of each scFv protein was obtained from 1 liter of the supernatant of cultured *Escherichia coli*. For CDR substitution, we chose a sequence of repetitive non-charged small (Gly/Ser) residues that are commonly used for the inactivation of specific domains (21). Each scFv was named according to the position of the CDR replaced with Gly/Ser residues. For example, 3D8-H1i denotes an scFv in which HCDR1 of 3D8 was replaced, and 3D8-L3i denotes an scFv in which LCDR3 was replaced.

Secondary Structure Analysis of scFv Variants—Because the deactivation of any CDR may cause improper folding of scFv, the secondary structures of the six purified scFv variants were monitored by far-UV CD spectroscopy. The far-UV CD spectra of the three 3D8-Hi (Fig. 2A) and three 3D8-Li variants (Fig. 2B) showed that their secondary structures were predominantly β-sheets, as expected for typical members of the functional immunoglobulin family, including scFvs (22, 23). These data indicate that all scFv variants folded properly and that single CDR deactivations in 3D8 scFv did not cause significant structural distortions.

DNA Binding Activity of scFv Variants—We first measured the affinity of the CDR-deactivated scFvs for a synthetic ss-(dN)₄₀ DNA using SPR (Table 1). Wild-type 3D8 scFv bound to ss-(dN)₄₀ in a concentration-dependent manner, with an affinity similar to that reported previously (15). From the kinetic binding parameters, *K*ₐ and *k*ₐ, we calculated the *K*ₐ of wild-type 3D8 scFv to be ~41 nM. The binding affinities of the 3D8-Hi variants were either slightly higher (2-fold higher for 3D8-H2i) or lower (2–5-fold lower for 3D8-H1i and 3D8-H3i). With respect to the 3D8-Li variants, the affinities of 3D8-L2i and 3D8-L3i were either slightly higher (4-fold) or lower (3-fold) than that of the wild-type scFv. However, 3D8-L1i did not bind to ss-(dN)₄₀. BSA (100 μg/mL; negative control) did not bind to the surface of the ss-(dN)₄₀-immobilized chip (data not shown). Taken together, these data indicate that the DNA binding activity of 3D8 is not completely abolished by the deactivation of a single CDR, except in the case of the LCDR1. This suggests that LCDR1 may be crucial for the DNA binding activity and/or structural stability of scFv.

Cell Penetration and Heparin Binding of the scFvs—We next analyzed uptake of the different scFvs in permeabilized HeLa cells and the amount of scFv bound to the surface of non-permeabilized cells by flow cytometry. Cells were incubated with the scFvs for 6 h at 37 °C. The cell membranes were then fixed and either permeabilized or not to distinguish cell surface-bound (Fig. 3A, 3B, and 3C, left panels) from endocytosed scFv (Fig. 3A, 3B, and 3C, right panels). Compared with wild-type 3D8 scFv, the three 3D8-Hi variants were internalized much less efficiently, and large amounts of 3D8-H2i and 3D8-H3i proteins remained bound to cell surface after washing (Fig. 3A). For the 3D8-Li variants, 3D8-L3i was endocytosed to the same extent as the wild-type 3D8 scFv, whereas 3D8-L1i and 3D8-L2i neither bound to nor entered the cells (Fig. 3B). The negative control, HW6 scFv, did not generate a signal. The flow cytometry data with permeabilized cells were supported by confocal microscopy (Fig. 3C). Thus, the cell-penetrating activity of 3D8 scFv was relatively resistant to the deactivation of LCDR3 compared with deactivation of the other CDRs.

Previous studies suggest that heparan sulfate proteoglycans function as cell surface receptors that recognize anti-DNA Abs, and that anti-DNA Abs cross-react with negatively charged heparan sulfate epitopes (7, 24–26). Therefore, we next examined the heparin binding activity of the 3D8 variants. We found that 3D8-H2i, 3D8-H3i, and 3D8-L3i bound strongly to heparin, a soluble heparan sulfate analog, in a manner comparable with the affinity similar to that reported previously (15). From the kinetic binding parameters, *K*ₐ and *k*ₐ, we calculated the *K*ₐ of wild-type 3D8 scFv to be ~41 nM. The binding affinities of the 3D8-Hi variants were either slightly higher (2-fold higher for 3D8-H2i) or lower (2–5-fold lower for 3D8-H1i and 3D8-H3i). With respect to the 3D8-Li variants, the affinities of 3D8-L2i and 3D8-L3i were either slightly higher (4-fold) or lower (3-fold) than that of the wild-type scFv. However, 3D8-L1i did not bind to ss-(dN)₄₀. BSA (100 μg/mL; negative control) did not bind to the surface of the ss-(dN)₄₀-immobilized chip (data not shown). Taken together, these data indicate that the DNA binding activity of 3D8 is not completely abolished by the deactivation of a single CDR, except in the case of the LCDR1. This suggests that LCDR1 may be crucial for the DNA binding activity and/or structural stability of scFv.

Cell Penetration and Heparin Binding of the scFvs—We next analyzed uptake of the different scFvs in permeabilized HeLa cells and the amount of scFv bound to the surface of non-permeabilized cells by flow cytometry. Cells were incubated with the scFvs for 6 h at 37 °C. The cell membranes were then fixed and either permeabilized or not to distinguish cell surface-bound (Fig. 3A, 3B, and 3C, left panels) from endocytosed scFv (Fig. 3A, 3B, and 3C, right panels). Compared with wild-type 3D8 scFv, the three 3D8-Hi variants were internalized much less efficiently, and large amounts of 3D8-H2i and 3D8-H3i proteins remained bound to cell surface after washing (Fig. 3A). For the 3D8-Li variants, 3D8-L3i was endocytosed to the same extent as the wild-type 3D8 scFv, whereas 3D8-L1i and 3D8-L2i neither bound to nor entered the cells (Fig. 3B). The negative control, HW6 scFv, did not generate a signal. The flow cytometry data with permeabilized cells were supported by confocal microscopy (Fig. 3C). Thus, the cell-penetrating activity of 3D8 scFv was relatively resistant to the deactivation of LCDR3 compared with deactivation of the other CDRs.

Previous studies suggest that heparan sulfate proteoglycans function as cell surface receptors that recognize anti-DNA Abs, and that anti-DNA Abs cross-react with negatively charged heparan sulfate epitopes (7, 24–26). Therefore, we next examined the heparin binding activity of the 3D8 variants. We found that 3D8-H2i, 3D8-H3i, and 3D8-L3i bound strongly to heparin, a soluble heparan sulfate analog, in a manner comparable
with that of the wild-type scFv, whereas the negative controls (HW6 scFv and DNase I) did not bind to heparin (Fig. 4A). 3D8-H2i, 3D8-H3i, and 3D8-L3i were also shown to be DNA binders (Table 1). Moreover, DNA binding of the strong heparin binders (3D8-H2i, 3D8-H3i, and wild-type 3D8 scFv) was inhibited by heparin in a concentration-dependent manner (Fig. 4B), indicating that heparan sulfate competes for the DNA-binding site of these scFvs. Taken together, the heparin binding activity of the scFvs correlated to either their cell surface binding (for 3D8-H2i and 3D8-H3i) or cell-penetrating (for 3D8-L3i and wild-type 3D8 scFv) activities, although cell surface binding was not necessarily correlated with cellular internalization.

**DNA-hydrolyzing Activity of the scFvs**—The DNA-hydrolyzing activity of the different scFv constructs was analyzed using a FRET-based DNA cleavage assay in which the hydrolysis of a DNA substrate double-labeled with a fluorophore at the 5’ terminus and its quencher at the 3’ terminus was measured.
according to the increase in fluorescence intensity. The assay was performed in the presence or absence of heparin, which competes with the 3D8 scFvs for DNA-binding sites (Fig. 4B).

We hypothesized that if the DNA-hydrolyzing activity of the 3D8 scFvs was inhibited by heparin, then this would rule out any false positives caused by contamination. The DNA-hydrolyzing activity of wild-type 3D8 scFv was completely blocked by heparin; however, the DNA-hydrolyzing activity of DNase I, which does not bind to heparin, was not affected by heparin as expected (Fig. 5). At least three scFv variants, 3D8-H3i (Fig. 5A), 3D8-L2i, and 3D8-L3i (Fig. 5B), retained DNA-hydrolyzing activity in the absence of heparin, although the activity of 3D8-H3i was reduced by 45% and that of 3D8-L2i and 3D8-L3i was reduced by 75%. None of the 3D8 variants showed DNA-hydrolyzing activity in the presence of heparin, confirming that the DNA-hydrolyzing activity of scFv is due to the 3D8 proteins rather than to any contaminating proteins.

Properties of CDR-derived Peptides—We analyzed the DNA binding/hydrolyzing, heparin binding, and cell-penetrating activities of CDR-derived peptides that were N-terminally labeled with either biotin or FITC. The amino acid sequence, length, and pI value of the six peptides corresponding to the CDRs of 3D8 scFv are shown in Table 2. Also shown are two control peptides: a positive control pep-Tat, which has a high cell penetration efficiency (28), and a negative control pep-VHFR3 derived from a part of the FR (framework region) in the 3D8 heavy chain.

ELISA results showed that the pI value of the peptide was directly proportional to its DNA binding (Fig. 6A) and heparin binding (Fig. 6B) activity. The degree of binding activity was

| Peptide | Amino acid sequence | Length | pI |
|---------|---------------------|--------|----|
| pep-H1  | SYVMH               | 5      | 6.5|
| pep-H2  | YINPYNGTK           | 10     | 5.8|
| pep-H3  | GAYKRYAMDY          | 11     | 8.4|
| pep-L1  | KSSQSLNSRTRKLYA    | 17     | 11.1|
| pep-L2  | WASTRES             | 7      | 6.0|
| pep-L3  | KQSYHYMHYT          | 9      | 8.4|
| pep-VHFR3| KSSSTAYMEL        | 10     | 6.0|
| pep-Tat | GRKRRQRRRPPQ       | 13     | 12.7|

pep-Tat (pI 12.7) > LCDR1 peptide (pep-L1; pI 11.1). Thus, electrostatic interactions between the basic residues within the proteins and the negatively charged DNA and heparin molecules may be the primary factor that determines the strength of binding. None of the CDR-derived peptides showed DNA-hydrolyzing activity (Fig. 6C). Only the pep-H1 and pep-H2 peptides showed cell-penetration activity, but the level of entry was <10% that observed for the Tat control peptide (Fig. 6D). A representative confocal microscopic image of the internalized pep-H1 is shown in Fig. 6E. These data indicate that the amino acid sequence of a CDR-derived peptide, rather than its pI, determines whether it is internalized by a cell. We expected pep-L1 to penetrate the cells because LCRD1-deactivated scFv failed to show either DNA binding or cell penetration activity;
however, pep-L1 did not penetrate the cells. This suggests that soluble pep-L1 may have a bioactive behavior different from that when it is incorporated between the FRs.

**Properties of the Hybrid Ab, HW6/3D8L1**—To further identify the role of 3D8-LCDR1, we generated a hybrid Ab HW6/3D8L1 in which the LCDR1 of HW6 scFv (human anti-DR5 (death receptor 5)) was replaced with the LCDR1 from 3D8 (KSSQSLFNSRTRKNYLA: 17 amino acids). HW6/3D8L1 did not retain DR5 binding activity (Fig. 7A) but acquired the DNA binding (Fig. 7B), heparin binding (Fig. 7C), cell-penetrating (Fig. 7, D and E), and DNA-hydrolyzing (Fig. 7F) activities of the wild-type 3D8 scFv, although DNA-hydrolyzing activity was reduced by ~50% compared with wild-type 3D8 scFv. The CD spectra of HW6/3D8L1 showed a predominantly β-sheet secondary structure, similar to wild-type 3D8 (Fig. 7G). Taken together, the findings suggest that HW6/3D8L1 folds properly and exhibits properties similar to that of wild-type 3D8 scFv. Considering the unremarkable features of LCDR1 shown in Fig. 5, it appears that the LCDR1 of 3D8 is fully functional only when incorporated into an appropriate protein scaffold.

**DISCUSSION**

The present study investigated for the first time the functional consequences of deactivating the CDRs of Abs that have multiple activities, such as 3D8 scFv. Interestingly, the activities of the CDR-deactivated scFv variants were affected differently (unaffected or only partially affected), depending on which CDR was deactivated, and deactivation of LCDR1 abolished all activities. The DNA binding activity of 3D8 scFv was relatively resistant to the deactivation of single CDRs. This observation was unexpected considering the properties of mouse anti-DNA mAb 9D7, which is also able to penetrate cells; a single amino acid change (from Arg to Ala) within either the HCDR2 or HCDR3 region significantly decreased both its DNA binding and cell-penetration activities (7).

Our previous study revealed the importance of His residues within HCDR1 and LCDR3 of 3D8 scFv for DNA hydrolysis (15). However, substituting Ala residues for His within HCDR1 and LCDR3 did not affect its DNA binding capacity. This demonstrates that DNA binding and DNA hydrolysis can be separately manipulated by changing critical portions of the CDR. Our results showed that the DNA binding, DNA-hydrolyzing, and cell-penetrating activities of 3D8 scFv can be selectively manipulated by deactivating different CDRs.

Few studies have been conducted on the functional consequences of single complete CDR-scaled changes in Ab. This may be due to the commonly held view that the properties of an

---

3 J. Lee, H.-J. Kim, J. Roh, Y. Seo, M. Kim, H.-R. Jun, C. D. Pham, and M.-H. Kwon, unpublished data.
Ab are dependent upon the combined function of all six CDR loops; therefore, deactivation of a single complete CDR loop would be expected to severely impair Ab activity and structure. Furthermore, substitutions or insertions of amino acids within the CDRs have a marked impact on Ab affinity (7, 29–31) and aggregation (32). However, contrary to this concern, we observed that the (Gly/Ser)$_n$ grafted into the loop structures of each CDR are stabilized by the $\beta$-sheet FRs of the variable domains of 3D8 Ab (Fig. 2). All scFv variants generated for this study were amply obtained (2–5 mg/liter) from the supernatant of bacterial culture in a soluble form, not as intracellular inclusion bodies formed by the aggregation of misfolded proteins. Therefore, it appears that 3D8 scFv can structurally accommodate single CDR deactivation. However, although CDR deactivation worked well for the identification of functional CDRs in the multifunctional mAb 3D8 scFv, this strategy may not be applicable to the majority of mAbs. Studies with a variety of multifunctional mAbs will be needed to know if this strategy can be applied to other mAbs.

We reported previously that the H$_3$Tat-3D8 Ab, in which HCDR3 of 3D8 is replaced with a basic Tat peptide, acquired properties associated with the Tat peptide with no distortion of the intrinsic activities of the parent 3D8 Ab (10). Our current finding is consistent with the pliability of HCDR3 of 3D8 in that deactivation of HCDR3 affected DNA binding/hydrolysis and the cell-penetrating activity of 3D8 scFv to a much lesser extent than that of the other CDRs (Table 1 and Figs. 3 and 5). Functional peptides generated from non-Ab proteins can be grafted into the CDR loops of Ab scaffolds to create functionalized Abs with a similar or higher affinity for antigens and a longer half-life than the original peptides (26–28). HCDR3 of 3D8 may be a potential target region into which a functional peptide can be grafted to create a newly functionalized Ab protein.
CDR deactivation in a Multifunctional Anti-nucleic Acid Antibody

The LCDR1 peptide (17 amino acids) of 3D8, which is not flanked by FRs and may lack a stable tertiary structure, showed no DNA hydrolysis or cell-penetration activity except for low levels of DNA and heparin binding (Fig. 6). This is in contrast to reports showing that the CDR2-CDR3 peptide of the cell-penetrating anti-DNA mAb F4.1 can penetrate cells (10) and that CDR-derived peptides could function in a manner similar to that of the original Ab (10, 18).

Our conclusion that LCDR1 of 3D8 is the most important domain in terms of activity is supported by the observations that (1) deactivation of LCDR1 abolished all 3D8 activities, and that (2) surprisingly, grafting LCDR1 of 3D8 into an appropriate protein scaffold, such as HW6 scFv, was sufficient to confer DNA binding and cell-penetrating activities similar to those of the parent 3D8 scFv as well as a significant amount (50%) of DNA binding and cell-penetrating activity (Fig. 7). Interestingly, the DNA-hydrolyzing activity of HW6/3D8L1 was comparable to that of humanized 3D8 scFv, in which all six CDRs of 3D8 were grafted into corresponding human FRs (data not shown).

The function of the 3D8 LCDR1 domain might only be expressed when it is grafted into mAbs that possess adequate FRs, as in the case of mAb HW6. Actually, when we transferred the LCDR1 domain of 3D8 scFv into a chicken scFv mAb that is specific for the sporozoite antigen of the parasite *Eimeria tenella*, the hybrid Ab did not exhibit any of the activities of 3D8 scFv (data not shown). A full understanding of the role of the 3D8 LCDR1 domain in mAb function could be obtained by investigating whether the transfer of this domain into a wide range of mAbs results in their functionalization. In the protein engineering field, functional CDRs derived from Abs have been grafted into non-Ab scaffold proteins such as GFP, neocarzinostatin, and human fibronectin to create functionalized proteins (33–35). It may be worthwhile grafting the 3D8 LCDR1 domain onto these non-Ab scaffolds.

In conclusion, the present study showed that the deactivation of single CDRs in 3D8 scFv resulted in 3D8 scFvs with different properties and revealed an important role for LCDR1 in all 3D8 scFv activities (DNA binding, DNA hydrolysis, and cell penetration). This specific, whole CDR-deactivating strategy, rather than the commonly employed point-mutational strategy, might provide insight into the molecular properties of multifunctional Abs and allow the identification of functional CDRs in a variety of Abs.

REFERENCES

1. Putterman, C. (2004) New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. *Autoimmun. Rev.* 3, 7–11
2. Schroeder, K., Herrmann, M., and Winkler, T. H. (2013) The role of somatic hypermutation in the generation of pathogenic antibodies in SLE. *Autoimmunity* 46, 121–127
3. Rahman, A., Latchman, D. S., and Isenberg, D. A. (1998) Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. *Semin. Arthritis Rheum.* 28, 141–154
4. Radic, M. Z., and Weigert, M. (1994) Genetic and structural evidence for antigen selection of anti-DNA antibodies. *Annu. Rev. Immunol.* 12, 487–520
5. Wellmann, U., Letz, M., Herrmann, M., Angermüller, S., Kalden, J. R., and Winkler, T. H. (2005) The evolution of human anti-double-stranded DNA autoantibodies. *Proc. Natl. Acad. Sci. U.S.A.* 102, 9258–9263
6. Jang, E. J., Nahm, D. H., and Jang, Y. J. (2009) Mouse monoclonal autoantibodies penetrate mouse macrophage cells and stimulate NF-κB activation and TNF-α release. *Immunology letters* 124, 70–76
7. Song, Y. C., Sun, G. H., Lee, T. P., Huang, J. C., Yu, C. L., Chen, C. H., Tang, S. J., and Sun, K. H. (2008) Arginines in the CDR of anti-dsDNA autoantibodies facilitate cell internalization via electrostatic interactions. *Eur. J. Immunol.* 38, 3178–3190
8. Zack, D. J., Stempniak, M., Wong, A. L., Taylor, C., and Weisbart, R. H. (1996) Mechanisms of cellular penetration and nuclear localization of an anti-double-strand DNA autoantibody. *J. Immunol.* 157, 2082–2088
9. Yanase, K., and Madaio, M. P. (2005) Nuclear localizing anti-DNA antibodies enter cells via caveolae and modulate expression of caveolin and p53. *J. Autoimmun.* 24, 145–151
10. Ternynck, T., Avrameas, A., Ragimbeau, J., Buttin, G., and Avrameas, S. (1998) Immunoochemical, structural and translocating properties of anti-DNA antibodies from (NZBxNZW)F1 mice. *J. Autoimmun.* 11, 511–521
11. Hansen, J. E., Chan, G., Liu, Y., Hegan, D. C., Dalal, S., Dray, E., Kwon, Y., Xu, Y., Xu, X., Peterson-Roth, E., Geiger, E., Liu, Y., Gera, J., Sweeney, J. B., Sung, P., Rockwell, S., Nishimura, R. N., Weisbart, R. H., and Glazer, P. M. (2012) Targeting cancer with a lupus autoantibody. *Sci. Transl. Med.* 4, 157ra142
12. Gololobov, G. V., Rumbley, C. A., Rumbley, J. N., Schourov, D. V., Makarevich, O. I., Glibob, A. G., Voss, E. W., Jr., and Rodkey, L. S. (1997) DNA hydrolysis by monoclonal anti-ssDNA autoantibody BV 04–01. Origins of catalytic activity. *Mol. Immunol.* 34, 1083–1093
13. Lee, E. J., Jang, E. J., Lee, E., Yu, J., Chung, H. Y., and Jang, Y. J. (2007) Cell-penetrating autoantibody induces caspase-mediated apoptosis through catalytic hydrolysis of DNA. *Bioorg. Med. Chem.* 15, 2016–2023
14. Jang, J. Y., Jeong, J. G., Jun, H. R., Lee, S. C., Kim, J. S., Kim, Y. S., and Kwon, M. H. (2009) A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity. *Cell. Mol. Life Sci.* 66, 1985–1997
15. Kim, Y. R., Kim, J. S., Lee, S. H., Lee, W. R., Sohn, J. N., Chung, Y. C., Shim, H. K., Lee, S. C., Kwon, M. H., and Kim, Y. S. (2006) Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity. *J. Biol. Chem.* 281, 15287–15295
16. Pham, C. D., Woo, M. Y., Kim, Y. S., Park, S., and Kwon, M. H. (2012) An anti-nucleic acid antibody delivers antigen to the cross-presentation pathway in dendritic cells and potentiates therapeutic antitumor effects. *J. Immunol.* 189, 5755–5763
17. Jeong, J. G., Kim, D. S., Kim, Y. S., and Kwon, M. H. (2011) A Tat-grafted anti-nucleic acid antibody acquires nuclear-localization property and a preference for TAR RNA. *Biochem. Biophys. Res. Commun.* 406, 403–407
18. Qiu, X. Q., Wang, H., Cai, B., Wang, L. L., and Yue, S. T. (2007) Small antibody mimetics comprising two complementarity-determining regions directed to new targets of B16F10-Nex2 melanoma cells. *Transl. Oncol.* 3, 204–217
19. Jakobi, A. J., Mashaghi, A., Tans, S. J., and Huizinga, E. G. (2011) Calcium modulates force sensing by the von Willebrand factor A2 domain. *Mol. Recognit.* 25, 921–929
20. Timmerman, P., Shochat, S. G., Desmet, J., Barderas, R., Casal, J. L., Meloen, R. H., and Altschuh, D. (2010) Binding of CDR-derived peptides is mechanistically different from that of high-affinity parental antibodies. *J. Mol. Recognit.* 23, 559–568
21. Dobroz, A. S., Rodrigues, E. G., Juliano, M. A., Fraça, D. M., Nakayasu, E. S., Almeida, I. C., Mortara, R. A., Jacobs, J. F., Amanante-Mendes, G. P., Magliani, W., Conti, S., Polonelli, L., and Travassos, L. R. (2010) Differential antitumor effects of IgG and IgM monoclonal antibodies and their synthetic complementarity-determining regions directed to new targets of B16F10-Nex2 melanoma cells. *Transl. Oncol.* 3, 204–217
22. Jakobi, A. J., Mashaghi, A., Tans, S. J., and Huizinga, E. G. (2011) Calcium modulates force sensing by the von Willebrand factor A2 domain. *Nat. Commun.* 2, 385
23. Greenfield, N. J. (2006) Using circular dichroism spectra to estimate protein secondary structure. *Nat. Protoc.* 1, 2876–2890
24. Lupinek, C., Roux, K. H., Laffer, S., Rauter, I., Regnald, K., Kneidinger, M., Blatt, K., Ball, T., Pree, I., Jahn-Schmid, B., Allam, J. P., Novak, N., Drescher, A., Kricke, F., Valentin, P., England, H., and Valenta, R. (2009) Tri-molecular complex formation of IgE, FceRI, and a recombinant nonana-phylactic single-chain antibody fragment with high affinity for IgE.
24. Berden, J. H., Termaat, R. M., Brinkman, K., Smeenk, R. J., Swaak, A. J., Faaber, P., Assmann, K., van de Heuvel, L. P., and Veerkamp, J. H. (1989) Binding of anti-DNA antibodies to glomerular heparan sulfate. A new clue for the pathogenesis of SLE nephritis? Nephrologie 10, 127–132

25. Krishnan, M. R., Wang, C., and Marion, T. N. (2012) Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Kidney Int. 82, 184–192

26. Faaber, P., Rijke, T. P., van de Putte, L. B., Capel, P. J., and Berden, J. H. (1986) Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. J. Clin. Invest. 77, 1824–1830

27. Deleted in proof

28. Gump, J. M., and Dowdy, S. F. (2007) TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol. Med. 13, 443–448

29. Krause, J. C., Ekiert, D. C., Tumpey, T. M., Smith, P. B., Wilson, I. A., and Crowe, J. E., Jr. (2011) An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody. MBio 2, e00345–00310

30. Murakami, A., Takahashi, Y., Nishimura, M., Shimizu, T., and Azuma, T. (2010) The amino acid residue at position 95 and the third CDR region in the H chain determine the ceiling affinity and the maturation pathway of an anti-(4-hydroxy-3-nitrophenyl)acetyl antibody. Mol. Immunol. 48, 48–58

31. Clark, L. A., Boriack-Sjodin, P. A., Day, E., Eldredge, J., Fitch, C., Jarpe, M., Miller, S., Li, Y., Simon, K., and van Vlijmen, H. W. (2009) An antibody loop replacement design feasibility study and a loop-swapped dimer structure. Protein Eng. Des. Sel. 22, 93–101

32. Perchiacca, J. M., Bhattacharya, M., and Tessier, P. M. (2011) Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions. Proteins 79, 2637–2647

33. Nicaise, M., Valerio-Lepiniec, M., Minard, P., and Desmadril, M. (2004) Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold. Protein Sci. 13, 1882–1891

34. Kiss, C., Fisher, H., Pesavento, E., Dai, M., Valero, R., Ovecka, M., Nolan, R., Phipps, M. L., Velappan, N., Chasteen, L., Martinez, J. S., Waldo, G. S., Pavlik, P., and Bradbury, A. R. (2006) Antibody binding loop insertions as diversity elements. Nucleic Acids Res. 34, e132

35. Petrovskaya, L. E., Shingarova, L. N., Kryukova, E. A., Boldyreva, E. F., Yakimov, S. A., Guryanova, S. V., Novoseletsky, V. N., Dolgikh, D. A., and Kirpichnikov, M. P. (2012) Construction of TNF-binding proteins by grafting hypervariable regions of F10 antibody on human fibronectin domain scaffold. Biochemistry 77, 62–70